8:03 AM ET
8-K
M&A Deal
Azenta Signs $71M M&A Deal with SynPlexity Inc.
Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.
- Value
- $71M
- Counterparty
- SynPlexity Inc.
- Term
- 5 years